此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

膀胱切除手术技术的研究

2026年9月21日 更新者:Memorial Sloan Kettering Cancer Center

根治性膀胱切除术和术后护理改良的临床综合随机临床试验 (RCT)

The purpose of this study is to look at two standard surgical techniques used during a radical cystectomy and see whether they influence outcomes such as length of stay in the hospital and infections after surgery. This trial will evaluate whether the following surgical methods influence outcomes:

A ureteral stent is a thin tube that is placed in the ureter to drain urine from the kidney. Ureteral stents are often used to promote urine drainage after radical cystectomy, but may come at risk of urinary tract infection.

Alvimopan is a standard drug used to promote return of bowel function following surgery. Doctors do not know whether alvimopan is beneficial in current clinical practice.

The surgeon will decide whether participants will receive a stent and/or alvimopan, but if they are unsure what the best approach is, a surgical technique has been assigned by chance to them.

研究概览

地位

招聘中

条件

研究类型

介入性

注册 (估计的)

530

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Bernard Bochner, MD
  • 电话号码:646-422-4387

研究联系人备份

  • 姓名:Alvin Goh, MD
  • 电话号码:646-422-4667
  • 邮箱:goha@mskcc.org

学习地点

    • New Jersey
      • Basking Ridge、New Jersey、美国、07920
        • 招聘中
        • Memorial Sloan Kettering at Basking Ridge (Consent Only)
        • 接触:
          • Alvin Goh, MD
          • 电话号码:646-422-4667
      • Middletown、New Jersey、美国、07748
        • 招聘中
        • Memorial Sloan Kettering Monmouth (Consent Only)
        • 接触:
          • Alvin Goh, MD
          • 电话号码:646-422-4667
      • Montvale、New Jersey、美国、07645
        • 招聘中
        • Memorial Sloan Kettering Bergen (Consent Only)
        • 接触:
          • Alvin Goh, MD
          • 电话号码:646-422-4667
    • New York
      • Commack、New York、美国、11725
        • 招聘中
        • Memorial Sloan Kettering Suffolk-Commack (Consent Only)
        • 接触:
          • Alvin Goh, MD
          • 电话号码:646-422-4667
      • Harrison、New York、美国、10604
        • 招聘中
        • Memorial Sloan Kettering Westchester (Consent Only)
        • 接触:
          • Alvin Goh, MD
          • 电话号码:646-422-4667
      • New York、New York、美国、10065
        • 招聘中
        • Memorial Sloan Kettering Cancer Center (All Protocol Activites)
        • 接触:
          • Alvin Goh, MD
          • 电话号码:646-422-4667
      • Rockville Centre、New York、美国、11553
        • 招聘中
        • Memorial Sloan Kettering Nassau (Consent Only)
        • 接触:
          • Alvin Goh, MD
          • 电话号码:646-422-4667

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

21年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

Stent vs. no stent

  • Patients aged ≥21 years who are scheduled to undergo radical cystectomy for treatment of bladder cancer with one of the consenting surgeons Alvimopan vs. no alvimopan
  • Patients aged ≥21 years who are scheduled to undergo radical cystectomy for treatment of bladder cancer with one of the consenting surgeons

Exclusion Criteria:

Stent vs. no stent

  • No exclusion criteria

Alvimopan vs. no alvimopan

  • Patients on chronic opioid therapy are ineligible to receive alvimopan and will be excluded from this cohort of the trial

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:阶乘赋值
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Stent vs No Stent

For patients treated by a surgeon randomized to use ureteral stents, the operating surgeon may choose to use a single or double J ureteral stent (6- to 8.5-fr in size) or an alternative ureteral stent of the surgeon's choice to be placed across the ureteroenteric anastomosis intraoperatively. Because there is no standard ureteral stent size or type, the surgeon will select a stent type and size according to their experience and will document the stent size and type used. This is already routinely recorded as part of the standard of care at MSK.

Surgeon may choose to use a single or double J ureteral stent (6- to 8.5-fr in size) or an alternative ureteral stent of the surgeon's choice.

实验性的:Alvimopan vs No Alvimopan

For patients randomized to receive alvimopan, the patient will receive alvimopan as a fixed 12-mg dose, with the first dose administered 0.5 to 5 h before the start of surgery; administration will be continued with twice daily oral doses postoperatively until hospital discharge or a maximum of 7 days (15 in-hospital doses), as indicated on the medication's FDA label. This is the current standard of care for most cases at MSK.

Patient will receive alvimopan as a fixed 12-mg dose, with the first dose administered 0.5 to 5 h before the start of surgery; administration will be continued with twice daily oral doses postoperatively until hospital discharge or a maximum of 7 days (15 in-hospital doses).

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Length of hospital stay (Alvimopan)
大体时间:greater than 6 days

it will define success for the intervention as a length of stay <6 days (6 days is the current median length of stay).

greater than 6 days
Symptomatic urinary tract infections (Stents)
大体时间:within 30 days of surgery

defined as the presence of signs or symptoms indicative of infection (fever, flank or abdominal pain, leukocytosis, radiographic imaging consistent with pyelonephritis) and a positive urine culture (>100,000 CFU pathogenic bacteria on an appropriately collected urine specimen).

within 30 days of surgery

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Alvin Goh, MD、Memorial Sloan Kettering Cancer Center

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年11月21日

初级完成 (估计的)

2028年11月1日

研究完成 (估计的)

2028年11月1日

研究注册日期

首次提交

2024年11月21日

首先提交符合 QC 标准的

2024年11月21日

首次发布 (实际的)

2024年11月25日

研究记录更新

最后更新发布 (实际的)

2026年9月22日

上次提交的符合 QC 标准的更新

2026年9月21日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅